Report cover image

Psoriasis - Global Clinical Trials Review, 2025

Publisher GlobalData
Published Nov 27, 2025
Length 2015 Pages
SKU # GBDT20673383

Description

Psoriasis - Global Clinical Trials Review, 2025

Summary

GlobalData's clinical trial report, “Psoriasis - Global Clinical Trials Review, 2025 provides an overview of Psoriasis Clinical trials scenario. This report provides top line data relating to the clinical trials on Psoriasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

2015 Pages
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Psoriasis to Immunology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Psoriasis to Immunology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Psoriasis Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Psoriasis
Nov 17, 2025: Noxopharm : First dose in HERACLES clinical trial Part Two
Nov 10, 2025: Arctic Bioscience – Q3 2025 Operational update – Significant results on systemic inflammation
Oct 31, 2025: UNION therapeutics announces publication of biomarker modulation profile of orismilast using novel approach with tape-stripping and Olink technology
Oct 24, 2025: Icotrokinra Long-term Results of Targeted Oral Peptide With High Rates of Durable Skin Clearance and Favorable Safety Profile in Genital Psoriasis
Oct 10, 2025: Sareum Holdings Announces Update on toxicology study for SDC-1801
Sep 18, 2025: Almirall Presents Long-Term Results From First Real-World Dermatology Study Using Who-5 Well-Being Index as Primary Endpoint of Psoriasis at EADV 2025
Sep 17, 2025: Arcutis To Present Multiple New Zoryve (Roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
Sep 08, 2025: HERACLES Clinical Trial – Update 4
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Source
List of Tables
Table 1: Psoriasis Therapeutics, Global, Clinical Trials by Region, 2025*
Table 2: Psoriasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Table 3: Psoriasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Table 4: Psoriasis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
Table 5: Psoriasis Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
Table 6: Psoriasis Therapeutics Clinical Trials, North America, Top Countries, 2025*
Table 7: Psoriasis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
Table 8: Psoriasis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
Table 9: Proportion of Psoriasis to Immunology Clinical Trials, G7 Countries (%), 2025*
Table 10: Psoriasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Table 11: Psoriasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Table 12: Proportion of Psoriasis to Immunology Clinical Trials, E7 Countries (%), 2025*
Table 13: Psoriasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Table 14: Psoriasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Table 15: Psoriasis Therapeutics, Global, Clinical Trials by Phase, 2025*
Table 16: Psoriasis Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
Table 17: Psoriasis Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Table 18: Psoriasis Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Table 19: Psoriasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
Table 20: Psoriasis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
Table 21: Psoriasis Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Table 22: Psoriasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Table 23: Psoriasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
List of Figures
Figure 1: Psoriasis Therapeutics, Global, Clinical Trials by Region (%), 2025*
Figure 2: Psoriasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
Figure 3: Psoriasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
Figure 4: Psoriasis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
Figure 5: Psoriasis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
Figure 6: Psoriasis Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
Figure 7: Psoriasis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
Figure 8: Psoriasis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
Figure 9: Proportion of Psoriasis to Immunology Clinical Trials, G7 Countries (%), 2025*
Figure 10: Psoriasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
Figure 11: Psoriasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
Figure 12: Proportion of Psoriasis to Immunology Clinical Trials, E7 Countries (%), 2025*
Figure 13: Psoriasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
Figure 14: Psoriasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
Figure 15: Psoriasis Therapeutics, Global, Clinical Trials by Phase (%), 2025*
Figure 16: Psoriasis Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
Figure 17: Psoriasis Therapeutics, Global, Clinical Trials by Trial Status, 2025*
Figure 18: Psoriasis Therapeutics Clinical Trials, Global, by End Point Status, 2025*
Figure 19: Psoriasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
Figure 20: Psoriasis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
Figure 21: Psoriasis Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
Figure 22: Psoriasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
Figure 23: Psoriasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
Figure 24: GlobalData Methodology

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us